Central Government spends around 1.5% of GDP on healthcare. When measured on per-capita terms, India ranks 154th out of 195 countries in terms of access to healthcare, which is worse in comparison to the regional neighbours (Bangladesh, China, Pakistan and Sri Lanka), and even West African countries like Ghana and Liberia.
MR. CHEN was having cough and running temperatures. The family members mistook the symptoms for any other ordinary viral fever, until the time he started complaining about breathing difficulties when he got admitted in a hospital. Mr. Chen died on January 22 from pneumonia and acute respiratory disorder. The cause of death is a new trait of virus, currently named as coronavirus (2019-nCoV) which has its origin in the Hubei Province of China. As on January 26, at least 2,000 cases of coronavirus are reported and at least 56 people have died. The number is on the rise with every passing day.
As a precautionary measure, China has locked down Wuhan (the capital city of Hubei) by putting travel restrictions on around 20.5 million people. Unfortunately, cases of coronavirus are also getting reported from far-off places such as Saudi Arabia, Singapore, Europe, and Australia. During 2002-2003, outbreak of the SARS virus affected 8098 people and resulted in 774 deaths. How much prepared is India to handle such a health catastrophe? Some statistics will clear things up. Central Government spends around 1.5% of GDP on healthcare.
When measured on per-capita terms, India ranks 154th out of 195 countries in terms of access to healthcare, which is worse in comparison to the regional neighbours (Bangladesh, China, Pakistan and Sri Lanka), and even West African countries like Ghana and Liberia. Per-capita expenditure on health is less than $75 per year in comparison to $9536 for the US, and $4396 for the United Kingdom(World Development Indicators, World Bank, 2020). Chronic diseases are the biggest causes of death and disability in India. They account for more than 30% of deaths, with cardiovascular diseases and diabetes, respiratory conditions and cancers. As a way of intervention, the Government launched Ayushman Bharat (AB) programme. Under the AB programme, as of January 24, 2020, the Central Government has allocated Rs. 6,400 crore, generated 7.28 crore e-cards, and has empanelled 21,259 hospitals across India.
This is a welcome move. The question is about the implementation and effectiveness of the AB scheme. Consider this. AB is targeted towards the tertiary healthcare sector (extended medical procedure involving operation of heart, lungs, kidneys, etc.). With the current state of the Indian economy, there is every likelihood that the Government will not be able to allocate more resources towards the primary health care sector, dealing with chronic illness, maternity, and child care/birth. More importantly, to meet the target of AB programmes, the Government may have to squeeze out resources from the primary healthcare sector. Already, India is lower down the ladder when we compare level of per-capita income with other regional neighbours. In terms of availability of doctors and the number of hospital beds, India lags behind the prescribed World Health Organisation (WHO) standards. Even with the introduction of the AB, in rural India, almost 80% of the Out of Pocket (OOP) expenditure is on medicines, whereas in urban areas, the corresponding figure stands at around 75%.
The insurance coverage in India for both indoor and outdoor treatments continues to be narrow, despite the recent rise in the public-private partnerships (PPP) in health insurance, explaining why people have to rely on OOP. People meet their OOP – some 47% of the cost of hospital admissions in rural areas and 31% in urban areas – by borrowing and the sale of personal goods and assets. This affects their livelihoods and education of their children (with an impact on inter-generational income flow).
What are the factors that are contributing to the rise in the price of medicines and hence contributing to a negative health outcome? Most obviously, there is GST of 5% on most medicines – an extra 5% from the pockets of sick people. There is also a 12% GST on a wide range of other important medical supplies, including bandages and sterile gauze, diabetic monitoring equipment, photographic plates used in x-rays, etc. Even though India is a major manufacturer of medicines, it still relies on imports, particularly for more modern medicines required to tackle non-communicable diseases. India has one of the highest tariff rates when it comes to pharmaceutical imports. India is at the top (or more properly, bottom) five offenders on drug tariffs, with a levy of 10% across the board on all categories of imported medicines and vaccines. In addition to tariffs, there are major obstacles to trade in medicines, particularly at the border and behind borders.
These so-called Non-Tariff Measures (NTMs) include inefficient customs procedures, red-tape and hidden taxes. In India, around 3,958 instances of NTMs were reported on medicines, mainly on account of labelling and packaging requirements. Bureaucracy and red tape adds further delays of between 400 and 500 days, according to figures from the UK’s Centre for Innovation in Regulatory Science. Instead of reducing taxes and NTMs on medicine and medical products, there is an effort by the Government to cap the prices. This has resulted in artificial shortage and substandard quality of medical products available in the market. For example, after National Pharmaceutical Pricing Authority imposed a price cap on cardiac stents, there are reports that better quality stents are replaced with sub-standard quality stents, and also about shortage in availability of stents. These measures are more prohibitive on health outcomes than the usual suspect - a stronger Intellectual Property Rights (IPR) Regime.
The Indian Government’s National IPR Policy is a mellowed down version that purports to promote innovation and entrepreneurship while ensuring access to healthcare, food security, and environmental protection. No changes have been made to Section 3(D) of the Indian Patents Act, which prevents evergreening of drug patents. A lax patent regime may also disincentivise medical innovation. For example, India’s generic drug manufacturing industry constitutes a healthy 10% of the volume of the global pharmaceutical industry, but only 1.4% of the value. So next time, an outbreak such as coronavirus occurs, policymakers both in India and at WHO, should be mindful which interventions work better than others. (IPA) (The writer is Professor, Bennett University)